Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 48,438 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524
View directory record Official record
Conditions
Von Willebrand Disease, Type 3
Interventions
Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Month and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT03504423
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
CPI 613, mFolfirinox, Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
40
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 31, 2026, 6:51 AM EDT
Not listed Not applicable Interventional

'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients

NCT01874379
View directory record Official record
Conditions
Hip or Knee Replacement
Interventions
'M'-Technique®, Guided Imagery, Standard of Care
Other
Lead sponsor
Saint Clare's Health System
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 31, 2026, 6:51 AM EDT
Not yet recruiting Not applicable Interventional

Cardiometabolic & Cognitive Effects of Peanut Butter in Prediabetes

NCT07714096
View directory record Official record
Conditions
Prediabetes
Interventions
Peanut butter, Usual diet
Other
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder

NCT04664062
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence
Interventions
Medication Assisted Treatment
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 89 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Denver, Colorado • Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery

NCT01544062
View directory record Official record
Conditions
Acute Pain, Hyperalgesia
Interventions
IV acetaminophen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 31, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

NCT04106362
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Cetuximab, Cisplatin, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

NCT00458146
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 31, 2026, 6:51 AM EDT
Not listed Phase 1 Interventional

Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1

NCT00033046
View directory record Official record
Conditions
Cocaine-Related Disorders, Drug Administration Schedule, Infusions, Intravenous
Interventions
Modafinil
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Messages About Reduced Nicotine in Combusted Tobacco Products

NCT05506046
View directory record Official record
Conditions
Health Communication, Smoking, Smoking, Tobacco, Smoking Behaviors, Risk Behavior
Interventions
Reduced nicotine message exposure, Modified risk message exposure, Combined message exposure (reduced nicotine + modified risk), Control message exposure
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
18 Years and older
Enrollment
1,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety

NCT00842946
View directory record Official record
Conditions
Public Speaking, Social Fear
Interventions
Exposure w/ Acceptance-Based Rationale, Exposure w/ Habituation-Based Rationale
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional

The Efficacy of Distal Pharyngeal Airway for Oxygenation During TEE

NCT05974488
View directory record Official record
Conditions
Airway Obstruction
Interventions
McMurray Enhanced Airway, Nasal Cannula
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional

Strength After Breast Cancer

NCT06052488
View directory record Official record
Conditions
Breast Cancer
Interventions
Strength After Breast Cancer
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 6:51 AM EDT
Completed No phase listed Observational

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027
View directory record Official record
Conditions
Hemophilia A
Interventions
FVIII concentrate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
13
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273
View directory record Official record
Conditions
Liver Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting Phase 3 Interventional

Early Amiodarone in Shockable Cardiac Arrest

NCT06680869
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Amiodarone Hydrochloride Injection, Usual Care Protocol
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 6:51 AM EDT
Terminated Phase 1 Interventional

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

NCT00086983
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
becatecarin, oxaliplatin, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

PF-06372865 In Subjects With Chronic Low Back Pain

NCT02262754
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
PF-06372865, Placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT04455841
View directory record Official record
Conditions
Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Interventions
INCB000928, ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting No phase listed Observational

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

NCT00482794
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis

NCT02694666
View directory record Official record
Conditions
Falls Prevention
Interventions
Controlled whole-body vibration training
Other
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Completed No phase listed Observational

Chest Dysphoria in Transmasculine Spectrum Adolescents

NCT04195659
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Mastectomy and chest masculinization
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

NCT02407080
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
RG7388, Pegasys
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 31, 2026, 6:51 AM EDT